Jiangsu Cowin Biotech Co. Ltd. A (688426.SS) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · China · ISIN CNE100005NM2

Price
19.21 CNY
Market cap
2.16 bn CNY
P/E (2025)
–
P/S (2025)
11.17
Dividend yield
0.00 %
Net margin
-55.50 %
Return on equity (ROE)
-7.95 %
Return on assets (ROA)
-7.18 %

Jiangsu Cowin Biotech Co. Ltd. A financials

Fiscal year20242025
Revenue125.88 m CNY193.52 m CNY
Gross profit70.40 m CNY87.87 m CNY
Operating income-156.00 m CNY-120.36 m CNY
EBIT-163.31 m CNY-105.59 m CNY
Net income-157.21 m CNY-107.41 m CNY
Diluted EPS – continuing operations-1.40 CNY-0.95 CNY

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Jiangsu Cowin Biotech Co. Ltd. A

Jiangsu CoWin Biotech Co., Ltd. engages in the research, development, sales, testing, and technology services of biological reagents in China. The company offers RT-PCR, PCR, multiplex PCR, and qPCR; collection, such as cfDNA, fecal DNA, saliva DNA, and urine DNA storage tube, as well as other collection products; cfDNA, genomic DNA, FFPE DNA extraction, and plasmid kit; molecular raw materials; quantitative analysis, RNA sequencing, adapter, purification magbeads, DNA sequencing, and single cells sequencing products; molecular cloning, such as cloning reagents; nucleic acid residue and contamination screening reagent; and other products. It also provides gene synthesis, gene fragment, and codon optimization services. The company's products and services are used in infectious disease, eugenics and good parenting, and oncology applications. The company was founded in 2007 and is headquartered in Taizhou, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.